Bristol Myers Squibb (CELG-RI) Share-based Compensation (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Share-based Compensation data on file, last reported at $146.0 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $146.0 million, up 1.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $555.0 million (up 7.14% YoY), and the FY2025 annual result was $553.0 million, up 9.07% from the prior year.
• Share-based Compensation rose to $146.0 million in Q1 2026 per CELG-RI's latest filing, from $133.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $146.0 million in Q1 2026 and troughed at $107.0 million in Q1 2022.
• A 5-year average of $128.3 million and a median of $129.0 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation fell 29.14% in 2022, then advanced 18.1% in 2023.
• A 5-year view of Share-based Compensation shows it stood at $119.0 million in 2022, then advanced by 6.72% to $127.0 million in 2023, then declined by 5.51% to $120.0 million in 2024, then increased by 10.83% to $133.0 million in 2025, then advanced by 9.77% to $146.0 million in 2026.
• Business Quant data shows CELG-RI's Share-based Compensation at $146.0 million in Q1 2026, $133.0 million in Q4 2025, and $139.0 million in Q3 2025.